LYT-320

LYT-320 (also known as SPT-320) is an orally bioavailable prodrug of agomelatine developed using the Glyph platform by Seaport Therapeutics, a subsidiary of PureTech Health. The drug is designed to bypass first-pass hepatic metabolism by targeting absorption through the intestinal lymphatic system, which may increase bioavailability and reduce liver exposure compared to conventional agomelatine. This approach aims to lower effective dosing requirements and potentially eliminate the need for liver function monitoring—a limitation with standard agomelatine therapy due to hepatotoxicity risk. Mechanistically, LYT-320 acts as a melatonin MT1 and MT2 receptor agonist and a 5-HT2C serotonin receptor antagonist. It is being developed primarily for anxiety disorders (notably generalized anxiety disorder) and mood disorders such as major depressive disorder[4][5][8].

Brand names

GlyphAgo

Other names

Glyph-agomelatineagomelatine prodrug